Back to discover
Disease

Blindness

Late-stage therapeutic developmentEmerging researchSteady momentum
9
Publications
14
Clinical trials
7
Related conditions
3
Related proteins
2026
Latest publication
Current focus
Carrier biologyCis-trans-isomerases biologyTherapeutic developmentGenetics & risk factors
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Glaucoma: now and beyond.

Research2023-09-21Lancet (London, England)

Trachoma.

Research2022-05-26Nature reviews. Disease primers

Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.

Research2008-09-22Proceedings of the National Academy of Sciences of the United States of America

Global magnitude of visual impairment caused by uncorrected refractive errors in 2004.

Research2008-01-01Bulletin of the World Health Organization

The number of people with glaucoma worldwide in 2010 and 2020.

Research2006-03-01The British journal of ophthalmology

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q4 2027.
  • Active recent publication activity.
  • 1 industry development reported.

Clinical trials

11 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
14
All trials
3
Active
6
Late-stage
5
Completed
Late-stage studies
Recently completed

Research activity

9 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20062026
Most influential
Recent publications
Major themes8
  • Global Health4
  • Genetic Therapy2
  • Aging1
  • Artificial Intelligence1
  • Blindness1
  • Cochlear Implants1
  • Dependovirus1
  • Glaucoma1
Leading journals6
  • The Lancet. Global health2
  • Bulletin of the World Health Organization1
  • Disability and rehabilitation. Assistive technology1
  • Human gene therapy1
  • Lancet (London, England)1
  • Nature reviews. Disease primers1
Leading researchers8
  • Aleman TS2
  • Boye SL2
  • Byrne BJ2
  • Cideciyan AV2
  • Flotte TR2
  • Hauswirth WW2
  • Jacobson SG2
  • Kaushal S2
Affiliations (unnormalised)6
  • Moorfields Eye Hospital NHS Foundation Trust2
  • Anglia Ruskin University1
  • Brien Holden Vision Institute1
  • Clinical Research Department1
  • Copenhagen University Hospital1
  • Department of Mathematics and Data Science Institute1

Disease biology

3 matches

Key proteins & gene products studied in this disease. Number shows shared papers.

Related conditions

7 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Blindness is the inability to see or the loss of perception of visual stimuli. It can arise from diseases of the eye, optic nerve, optic chiasm, or brain pathways involved in vision, including the occipital lobe. The literature also treats blindness as a major outcome of visual impairment that may be addressed through rehabilitation.

Causes

Blindness can result from eye diseases, optic nerve diseases, optic chiasm diseases, or brain diseases affecting the visual pathways or occipital lobe. The supplied reviews also identify specific avoidable causes of blindness such as cataract, uncorrected refractive error, glaucoma, and trachoma. Some causes are preventable or treatable, while others lead to irreversible sight loss.

Pathophysiology

The biological basis of blindness depends on where the visual system is disrupted. In glaucoma, progressive loss of retinal ganglion cells leads to irreversible sight loss, and lowering intraocular pressure can slow vision loss. In trachoma, recurrent conjunctival infection and chronic inflammation can progress to cicatricial disease and trichiasis, eventually causing blindness.

Risk factors

Risk is increased by conditions that damage the eye, optic nerve, visual pathways, or occipital lobe. The reviews highlight ageing as a driver of the global burden of blindness and note that avoidable blindness is linked to cataract and uncorrected refractive error. For trachoma-related blindness, highest prevalence is reported in the poorest communities of low-income countries, particularly in sub-Saharan Africa.

Current standard of care

Management is described at the level of rehabilitation and treatment of underlying causes. For glaucoma, standard approaches include lowering intraocular pressure with laser treatments, topical medications, and surgery. More broadly, many causes of blindness are preventable or treatable, and rehabilitation is part of the care landscape for established vision loss.

AI-generated summary grounded in MeSH and 4 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE.

Identifiers
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.